The First Drug Acting on the Cause of Narcolepsy Could Reach Europe in a Year
5 Articles
5 Articles
Oveporextone has shown improvements in vigil, drowsiness, and cataplexy in two phase 3 trials and has already been approved in the United States.
The head of the Neurophysiology Service and the Dream Unit of the Hospital de la Ribera (Valencia) and member of the Spanish Dream Society (SES), Javier Puertas, hopes that in a period of six months to one year the European Medicines Agency (EMA) will approve 'Orzeyful' (oveporextona), the first drug to combat the cause of narcolepsy.
lacronicabadajoz.com
Between 15,000 and 25,000 people in Spain have narcolepsy, a chronic neurological sleep disorder suffered by journalist Jordi Évole who, on various occasions, has claimed a greater understanding of the disease. The positive thing is that sleep medicine experts hope that, very soon - between six months and one year - the drug oveporextone will be approved in Europe, the first to combat the cause of a disease that in many people is undiagnosed. "P…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
